Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene

Gene Therapy

Volumn 6, Issue 4, 1999, Pages 547-553

  Carrio M ^a   Romagosa, A ^b   Mercade E ^b   Mazo, A ^b   Nadal, M ^a   Gomez Foix A M ^b   Fillat, C ^a,c  

^a Institut de Recerca Oncologica   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

Adenovirus; Bystander effect; HSVtk; Pancreatic tumors; Retrovirus

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE; VIRUS ENZYME;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TRANSPLANTATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; METAPHASE; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; RETROVIRUS; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME;

ADENOCARCINOMA; ADENOVIRIDAE; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GANCICLOVIR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, VIRAL; GENETIC VECTORS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; PANCREATIC NEOPLASMS; RETROVIRIDAE; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; ANIMALIA; HERPES; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0032959726     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300846     Document Type: Article

References (24)

1. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. New Engl J Med 1992; 326: 455-465.
2. Beger HG, Link KH, Poch B, Gansauge F. Pancreatic cancer recent progress in diagnosis and treatment. In: Neoptolemos JP, Lemoine NR (eds). Pancreatic Cancer. Molecular and Clinical Advances. Blackwell: Oxford, 1996, pp 227-235.
3. Rigg A, Sikora K. Genetic prodrug activation therapy. Mol Med Today 1997; 3: 359-366.
4. Cheng YC et al. Unique spectrum of activity of 9-{(1,3-dihydroxy-2-propoxy)methyl}-guanine against herpes viruses in vitro and its mode of action against herpes symplex virus type 1. Proc Natl Acad Sci USA 1983; 80: 2167-2770.
5. Caruso M. Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase. Mol Med Today 1996; 2: 212-217.
6. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
7. Gagandeep S et al. Prodrug-activated gene therapy: involvement of an immunological component in the 'bystander effect'. Cancer Gene Ther 1996; 3: 83-88.
8. Colombo BM et al. The bystander effect: association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther 1995; 6: 763-772.
9. Elshami AA et al. Gap junctions play a role in the bystander effect of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Therapy 1996; 3: 85-92.
10. Vrionis FD et al. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Therapy 1997; 4: 577-585.
11. Ram Z et al. In situ retrovirus-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993; 53: 83-88.
12. Eastham JA et al. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by Ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 1996; 7: 515-523.
13. Haffe HA et al. Adenovirus-mediated IH vivo gene transfer and expression in normal rat liver. Nat Genet 1992; 1: 372-378.
14. Takamiya Y et al. An experimental model of retrovirus gene therapy for malignant brain rumors. J Neurosurg 1993; 79: 104-110.
15. Feng M et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat Biotechnol 1997; 15: 866-870.
16. Garcia C et al. Characterization of new human pancreatic cancer cell lines expressing p21 and Gadd45 by p53-independent pathways. Cancer Res 1998 (submitted).
17. Ishii-morita H et al. Mechanism of bystander effect killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Therapy 1997; 4: 244-251.
18. DiMaio JM et al. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 1994; 116: 205-213.
19. Rosenfeld ME et al. Pancreatic carcinoma cell killing via adenoviral mediated delivery of herpes simplex virus thymidine kinase gene. Ann Surg 1997; 225: 609-620.
20. Smiley WR et al. Establishment of parameters for optimal transduction efficiency and antitumor effects with purified high-titer HSVtk retroviral vector in established solid tumors. Hum Gene Ther 1997; 8: 965-977.
21. Kuriyama S et al. Tissue-specific expression of HSVtk gene can induce efficient antitumor effect and protective immunity to wild-type hepatocellular carcinoma. Int J Cancer 1997; 71: 470-475.
22. Link CJ, Moorman D. A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer. Hum Gene Ther 1996; 7: 1161-1179.
23. Becker TC et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Meth Cell Biol 1994; 43: 161-189.
24. Izquierdo M et al. Long-term rat survival after malignant brain tumor regression by retroviral gene therapy. Gene Therapy 1995; 2: 66-69.